Itolizumab
As of the edition of 20 October 2026, Itolizumab is an antibody: stopped in 2025; acts on CD6.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Antibody
- Registered trials
- 10, 3 stopped early
- Disease areas
- Immune system; Lungs and airways; Skin and connective tissue; Infections; Bones, joints and muscles; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route A because of this drug.
Companies on route A for this drug
In the product3 companies are on route A because of Itolizumab.
See the 3 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD6 | T-cell differentiation antigen CD6 | P30203 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 2 | 0 | 1 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 2 | 0 | 0 | 2 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Biotech Pharmaceutical | Lead sponsor of trials | 2014 to now |
| Biocon | Lead sponsor of trials | 2019 to now |
| Equillium | Lead sponsor of trials | 2022 to now |